Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations

Table 7

Subjects with Hb >11 g/dL, 12 g/dL, or Hb change ≥1 g/dL in Study 7 anytime from randomization to end of study (Safety Population).

	1500 mg IV iron ()	1000 mg IV iron ()	Hazard ratio (95% CI)
(%) of patients with Hb >11 g/dL	557 (56.1%)	504 (51.1%)	1.15 (1.02–1.30)
(%) of patients with Hb >12 g/dL	358 (28.6%)	251 (20.0%)	1.44 (1.23–1.70)
(%) of patients with Hb change ≥1 g/dL	610 (48.7%)	513 (41.0%)	1.27 (1.13–1.43)

Hb = hemoglobin.
Data on file, Luitpold Pharmaceuticals, Inc.